Authors: Burke, TA Zabinski, RA Pettitt, D Maniadakis, N Maurath, CJ Goldstein, JL

Citation: Ta. Burke et al., A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis, PHARMACOECO, 19(1), 2001, pp. 33-47

Authors: Pettitt, D Goldstein, JL McGuire, A Schwartz, JS Burke, T Maniadakis, N

Citation: D. Pettitt et al., Overview of the Arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib, RHEUMATOLOG, 39, 2000, pp. 33-42

Authors: Maniadakis, N Gray, A

Citation: N. Maniadakis et A. Gray, The economic burden of back pain in the UK, PAIN, 84(1), 2000, pp. 95-103

Authors: Maniadakis, N Gray, A

Citation: N. Maniadakis et A. Gray, Health economics and orthopedics, J BONE-BR V, 82B(1), 2000, pp. 2-8

Authors: Maniadakis, N Thanassoulis, E

Citation: N. Maniadakis et E. Thanassoulis, Assessing productivity changes in UK hospitals reflecting technology and input prices, APPL ECON, 32(12), 2000, pp. 1575-1589